drugset / Trial / NCT05822609
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Phase 2
Recruiting
60 enrolled
University of Washington
Juvenile Diabetes Research Foundation · collabProvidence Healthcare · collabUniversity of Colorado, Denver · collabUniversity of Toronto · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Timeline
- Start
- 2024-04-05
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 1 mg | — |